Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability
Authors
Keywords
-
Journal
PHARMACOGENOMICS
Volume 16, Issue 13, Pages 1513-1520
Publisher
Future Medicine Ltd
Online
2015-08-28
DOI
10.2217/pgs.15.93
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Efficacy of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Clinical Research
- (2015) Nicola C. Savill et al. CNS DRUGS
- Differential Response Profiles in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
- (2014) Linda A. Wietecha et al. CLINICAL PEDIATRICS
- Individualizing the Use of Medications in Children: Making Goldilocks Happy
- (2014) J S Leeder et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Challenges in CYP2D6 Phenotype Assignment from Genotype Data: A Critical Assessment and Call for Standardization
- (2014) J. Hicks et al. CURRENT DRUG METABOLISM
- Atomoxetine-Induced Increases in Monoamine Release in the Prefrontal Cortex are Similar in Spontaneously Hypertensive Rats and Wistar-Kyoto Rats
- (2014) Yukio Ago et al. NEUROCHEMICAL RESEARCH
- Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009–2011: Focus on clinical efficacy and safety
- (2013) Chris J Bushe et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Noradrenergic modulation of cognition: Therapeutic implications
- (2013) Samuel R Chamberlain et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children
- (2012) Li Yang et al. JOURNAL OF NEURAL TRANSMISSION
- Atomoxetine Use During a Period of FDA Actions
- (2012) Dongyi (Tony) Du et al. MEDICAL CARE
- Trends of Outpatient Prescription Drug Utilization in US Children, 2002-2010
- (2012) G. Chai et al. PEDIATRICS
- Pharmacokinetics, Safety, and Tolerability of Atomoxetine and Effect ofCYP2D6*10/*10Genotype in Healthy Japanese Men
- (2011) A. Matsui et al. JOURNAL OF CLINICAL PHARMACOLOGY
- An analysis of rat prefrontal cortex in mediating executive function
- (2011) Raymond P. Kesner et al. NEUROBIOLOGY OF LEARNING AND MEMORY
- Trends in the Prevalence of Developmental Disabilities in US Children, 1997-2008
- (2011) C. A. Boyle et al. PEDIATRICS
- Catecholamine influences on prefrontal cortical function: Relevance to treatment of attention deficit/hyperactivity disorder and related disorders
- (2011) Amy F.T. Arnsten et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- NICE guideline: attention deficit hyperactivity disorder
- (2010) M Atkinson et al. Archives of Disease in Childhood-Education and Practice Edition
- A Comparison of the Efficacy of Medications for Adult Attention-Deficit/Hyperactivity Disorder Using Meta-Analysis of Effect Sizes
- (2010) Stephen V. Faraone et al. JOURNAL OF CLINICAL PSYCHIATRY
- Recognition of Impaired Atomoxetine Metabolism Because of Low CYP2D6 Activity
- (2010) Maureen A. ter Laak et al. PEDIATRIC NEUROLOGY
- Polymorphism of human cytochrome P450 enzymes and its clinical impact
- (2009) Shu-Feng Zhou et al. DRUG METABOLISM REVIEWS
- Clinical Responses to Atomoxetine in Attention-Deficit/Hyperactivity Disorder: The Integrated Data Exploratory Analysis (IDEA) Study
- (2009) Jeffrey H. Newcorn et al. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
- Safety and Tolerability of Atomoxetine Over 3 to 4 Years in Children and Adolescents With ADHD
- (2009) Craig Donnelly et al. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
- A Haplotype of the Norepinephrine Transporter (Net) Gene Slc6a2 is Associated with Clinical Response to Atomoxetine in Attention-Deficit Hyperactivity Disorder (ADHD)
- (2009) Nicolas Ramoz et al. NEUROPSYCHOPHARMACOLOGY
- CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD
- (2007) Paula T. Trzepacz et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More